Showing results (611-620 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|September 7, 2013
Using the stated preference technique for eliciting valuations: the role of the payment vehicleDorte Gyrd-HansenPharmacoeconomics|May 3, 2013
Cost of illness in colorectal cancer: an international reviewChristine Kriza, Martin Emmert, Philip Wahlster, et al.Pharmacoeconomics|May 7, 2013
Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variabilityAnthony T Newall, Juan Pablo Dehollain, Prudence Creighton, et al.Pharmacoeconomics|July 26, 2014
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalNicholas R Latimer, Christopher Carroll, Ruth Wong, et al.Pharmacoeconomics|August 14, 2014
"Can we declare victory and move on?" The case against funding burden-of-disease studiesSteven KymesPharmacoeconomics|December 6, 2013
Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trialEdward C F Wilson, Ludmila Shulgina, Anthony P Cahn, et al.Pharmacoeconomics|May 18, 2012
Value of information and pricing new healthcare interventionsAndrew R Willan, Simon EckermannPharmacoeconomics|August 31, 2013
A person trade-off study to estimate age-related weights for health gains in economic evaluationStavros Petrou, Ngianga-Bakwin Kandala, Angela Robinson, et al.Pharmacoeconomics|October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalSophie Beale, Rumona Dickson, Adrian Bagust, et al.Pharmacoeconomics|July 9, 2013
Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilitiesChristopher McCabe, Richard Edlin, David Meads, et al.Pageof 335